Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

SOPHiA GENETICS, in collaboration with AstraZeneca, conducted a study that leveraged advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vibrio cholerae, is evolving in ways that make the disease more severe and harder to control, but until now, scientists have ...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...